CoChat

A Review of the Preclinical Development of Zaleplon, a Novel Non‐Benzodiazepine Hypnotic for the Treatment of Insomnia

Beer, B., Clody, D. E., Mangano, R., Levner, M., Mayer, P., Barrett, J. E. · 1997 · CNS Drug Reviews
Cited by 40

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

SUMMARY: Zaleplon (N‐[3‐(3‐cyanopyrazolo[l,5‐a]pyrimidin‐7‐y l)phenyl)]‐N‐ethylacetamide) is a non‐benzodiazepine sedative‐hypnotic with benzodiazepine‐like sedative effects, but with less apparent liability for accompanying undesirable side effects. Zaleplon displaces [3 H]flunitrazepam from rat cortical membranes with an IC 50 value of 200 nM and enhances t‐butylbicyclophosphorothionate [35 S]TBPS binding by 73%, suggesting pharmacological activity mediated by the GABA A benzodiazepine receptor complex. In various preclinical procedures such as motor activity, muscle relaxation, EEG, anticonvulsant activity, and vigilance, zaleplon produced effects similar to those of other sedative‐hypnotic compounds such as triazolam and flurazepam; furthermore, these effects, when evaluated, were reversed by the benzodiazepine receptor antagonist flumazenil. Zaleplon increased punished (conflict) responding in squirrel monkeys and rats and these effects were also antagonized by flumazenil. When established as a discriminative stimulus in rats at 3.0mg/kg i.p., zaleplon showed a dose‐related increase in drug‐appropriate responding up to the training dose and a correlated decrease in response rate. Triazolam (0.1 to 1.0 mg/kg), the benzodiazepine partial agonist Ro 17‐1812 (0.3 to 3.0mg/kg), and the triazolopyridine CL 218,872 (1.0 to 3.0 mg/kg) substituted consistently for zaleplon in all rats, whereas the imidazo‐pyridines zolpidem (3.0 to 10 mg/kg) and alpidem (10 to 30 mg/kg), the benzodiazepine partial agonist bretazenil (0.03 to 10 mg/kg) and the novel putative anxio‐lytic CL 273,547 (10 to 56 mg/kg) did not result in consistent drug‐appropriate responding in all rats. These results suggest that the effects of zaleplon are similar in many respects to other compounds acting at the benzodiazepine receptor complex but differ as well from both benzodiazepine and non‐ benzodiazepine drugs. This profile of activity, coupled with additional information in ancillary procedures, yields a pre‐clinical profile of a short‐acting sedative‐hypnotic non‐benzodiazepine that is currently in Phase III development for the treatment of sleep disturbances.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1527-3458.1997.tb00324.x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 40

Metadata

Authors
Beer, B., Clody, D. E., Mangano, R., Levner, M., Mayer, P., & Barrett, J. E.
Venue
CNS Drug Reviews
Publisher
Wiley
Published
1997-09
Volume
3
Issue
3
Pages
207-224
ISSN
  • 1080-563X (ISSN-L)
  • 1527-3458
OpenAlex
W2012011634
Cited by
40
References
1
FWCI
9.24
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Review of the Preclinical Development of Zaleplon, a Novel Non‐Benzodiazepine Hypnotic for the Treatment of Insomnia. https://app.cochat.ai/papers/10.1111/j.1527-3458.1997.tb00324.x
The paper
Beer, B., Clody, D. E., Mangano, R., Levner, M., Mayer, P., & Barrett, J. E. (1997). A Review of the Preclinical Development of Zaleplon, a Novel Non‐Benzodiazepine Hypnotic for the Treatment of Insomnia. CNS Drug Reviews. https://doi.org/10.1111/j.1527-3458.1997.tb00324.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.